This is unlikely to surprise some investors, but a new study has determined that advanced knowledge of Phase III clinical trials of new cancer meds and FDA decisions may affect the publicly traded shares prices of drugmakers.
The DSM is supposed to reflect the current knowledge in the field and some of the latest research is too new to use as a basis for changing the framework of how mental illness is diagnosed, say DSM leaders.